Lynne Elmore joined MUSC Hollings Cancer Center as the director of research development.
Daniel J. Drucker will be awarded the American Association for Cancer Research 21st AACR-Irving Weinstein Foundation Distinguished Lectureship during the 2025 AACR annual meeting, to be held April 25-30 in Chicago, Illinois.
The University of Texas MD Anderson Cancer Center announced an agreement to become a Women’s Cancer Partner with the Union for International Cancer Control, marking a significant collaboration to improve breast and cervical cancer care worldwide.
The American Cancer Society released Breast Cancer Statistics, 2024, the organization’s biennial update on breast cancer occurrence and trends in the United States.
New research on the possibility to kill TNBCs by hijacking signals that normally drive mammary gland involution was released in Nature.
The phase III KEYNOTE-689 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as a perioperative treatment for patients newly diagnosed with stage 3 or 4A, resected, locally advanced head and neck squamous cell carcinoma met its primary endpoint of event-free survival.
Continuity of Medicaid coverage increases the survival rates of children and adolescents with cancer, according to research published in JCO Oncology Practice.
A blood test, performed when metastatic prostate cancer is first diagnosed, can predict which patients are likely to respond to treatment and survive the longest.
A study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center revealed that common breast cancer treatments, including chemotherapy, radiation, and surgery, may accelerate the biological aging process in breast cancer survivors.
FDA approved Itovebi (inavolisib) with palbociclib (Ibrance) and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, human epidermal growth-factor receptor 2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.
